SEAD™ (abnormal uterine bleeding)
The SEAD™ has the potential of becoming a strong and attractive choice
of therapy in the worldwide GEA market through its simplicity,
cost-effectiveness and new and innovative yet gentle “substance-based Ablation” technology.
The proprietary IUB™ platform – shaped for women – is the ideal drug carrier for various indications.